



NIH AIDS Reagent Program

20301 Century Boulevard
Building 6, Suite 200
Germantown, MD 20874
USA

Phone: 240 686 4740
Fax: 301 515 4015
aidsreagent.org

DATA SHEET

Reagent:	HeLa CD4-Clone 6C Cells (HT4-6C)
Catalog Number:	459
Lot Number:	098325
Release Category:	C
Provided:	4.4 x 10 ⁶ cells/mL. Viability, 97.3%.
Cell Type:	Human cervical epithelial carcinoma. HeLa cells were infected with a retroviral vector expressing CD4 and NeoR. Clones were selected for neomycin resistance and screened for the presence of surface CD4 via indirect immunofluorescence.
Propagation Medium:	RPMI 1640, 90%; fetal bovine serum, 10%.
Freeze Medium:	RPMI 1640, 50%; fetal bovine serum, 40%; DMSO, 10%.
Growth Characteristics:	Rapid growth; repassage by trypsinizing every 4-7 days and splitting 1/20 to 1/100. Use when cell density is $\geq 3 \times 10^6$ cells in a 25 cm ² flask. Morphology is variable, epithelial.
Sterility:	Negative for mycoplasma, bacteria and fungi.
Description:	This cell expresses human CD4 protein on the cell surface and can be infected by most HIV isolates.
Special Characteristics:	Foci of HIV-1 infected cells can be detected by indirect immunoperoxidase or immunofluorescence using anti-HIV-1 serum or anti-HIV-1 monoclonal antibodies, or at a lower efficiency by syncytia formation. Cells can be grown in the presence of G418. Sensitivity of this lot for wild-type HIV is low. These cells are also infected with murine leukemia virus expressing the amphoteric MuLV envelope, and when infected by HIV, they can produce pseudotyped HIV particles with amphoteric MuLV envelope which are capable of infecting some CD4- human and non-human cells.

ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL, AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT, FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.

Recommended Storage: Liquid nitrogen.

Contributor: Dr. Bruce Chesebro.

References: Chesebro B, Wehrly K. Development of a sensitive quantitative focal assay for human immunodeficiency virus infectivity. *J Virol* **62**:3779-3788, 1988.

Chesebro B, Buller R, Portis J, Wehrly K. Failure of human immunodeficiency virus entry and infection in CD4-positive human brain and skin cells. *J Virol* **64**:215-221, 1990.

NOTE: Acknowledgment for publications should read "The following reagent was obtained through the NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH: HeLa CD4 (HT4-6C) from Dr. Bruce Chesebro." Also include the references cited above in any publications.

Scientists at for-profit institutions or who intend commercial use of this reagent must contact the NIH Office of Technology Transfer, Email: NIAIDAIDSReagent@niaid.nih.gov, before the reagent can be released. Please specify the name and a description of the intended use of the reagent.

Last Updated July 02, 2018

ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL, AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT, FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.